This Week in RadOnc - Vol. 3, October 16th, 2026


Volume 3, October 16th, 2026

Welcome back to This Week in Rad Onc!

This week’s evidence asks where precision adds value—and where promising technology still needs validation. ROAM strengthens the discussion of postoperative radiation for atypical meningioma, while ASTRO updates bring longer follow-up and important cautions about toxicity, crossover and local control. For treatment teams, new CBCT and electron-dosimetry studies sit alongside practical motion-management guidance. We also highlight therapist education, a reusable imaging resource and recruiting studies across major disease sites. The aim is to make each finding useful without overstating what it proves.

Best,

Michael K Owens​
Editor-in-Chief
​This Week in RadOnc


Table of Contents

  1. Takeaways of the Week: Links to some of the big takeaways from the past week.
  2. Notable Publications: Key findings from influential open-access research and conference abstracts shaping radiation oncology practice.
  3. Industry Updates: The latest developments in technology, regulation, reimbursement, and the business of radiation oncology.
  4. Spotlight on Patient Care: A closer look at a publicly shared clinical case or trial dataset, highlighting treatment approaches and reported outcomes.
  5. Clinical Trials to Watch: Recruiting and upcoming studies exploring new radiation oncology treatments, with key eligibility and participation details.

Takeaways of the Week

  • ROAM adds randomized evidence for adjuvant RT after complete resection of WHO grade 2 meningioma. The final paper and EANO presentation are counted once. Source​
  • I-SABR reports a six-year survival signal, but remains a phase II study with a borderline overall-survival confidence interval. Source​
  • SOAR-HN’s intention-to-treat toxicity comparison was nonsignificant; extensive crossover limits confident survival comparisons. Source​
  • Routine preventive cement augmentation after spine SRS did not reduce fracture incidence significantly in the preliminary randomized analysis. Source​
  • New VHEE phantom measurements and longitudinal CBCT features support technical development; neither establishes improved patient outcomes. Source​
  • Tampere’s rectal program uses iridium-192 HDR brachytherapy. Its planned NORPPA-2 study has not reported efficacy results. Source​
  • The cervical intensification trial’s registry location list changed this week. Trial coverage uses site-level recruiting status, with a new adaptive NPC selection. Source​
  • HEAD-NECK-PET-CT offers planning and outcome research material, but its imaging is controlled access; the public tables have a different license. Source​

Academic Publication Review

This week, our selection includes 2 breaking reports, 1 from the past month, 1 from the last six months, and 5 ASTRO abstracts. Conference findings remain preliminary. Public abstract access does not confer an open reuse license.

BREAKING

1. VHEE: experimental validation before clinical translation

Anthropomorphic phantom dosimetry and validation of 150–200 MeV very high-energy electron radiotherapy at CERN

Fabio S. D’Andrea; Adam H. Aitkenhead; Robert Chuter; et al.
Communications Physics • Published 2026-10-09
Head and neck phantom / multiple sites • Very high-energy electrons / Monte Carlo
Keywords: VHEE · Dosimetry · Monte Carlo

CERN measurements at 150–200 MeV provide an experimental benchmark for very high-energy electron dose calculations. At 200 MeV, most head-and-neck phantom comparisons achieved high agreement, but one oblique multi-spot comparison had an 81.9% gamma pass rate. The work supports model validation and accelerator development. Ultra-high instantaneous dose rates were measured; no biological FLASH effect or patient benefit was tested.

DOI: 10.1038/s42005-026-02857-4​
​Open-access full text • CC BY 4.0

Technical validation, not clinical efficacy. Gamma results depend on the reported 1%/1 mm global normalization and 20% threshold.

BREAKING

2. Daily CBCT as a research tool for treatment response

A registration-consistent longitudinal CBCT framework for quantifying treatment-induced tumour texture changes in head and neck radiotherapy

Greta Karpaviciene; Diana Meilutyte-Lukauskiene; Reda Cerapaite-Trusinskiene; et al.
BMC Medical Imaging • Published 2026-10-09
Head and Neck • Daily CBCT / radiomics
Keywords: CBCT · Radiomics · Adaptive RT

A 30-patient study aligned daily CBCT tumor volumes to examine texture changes during head-and-neck treatment. Coarseness showed more stable longitudinal behavior than entropy or strength. This is a useful framework for studying routine treatment images, but the features have not been prospectively validated against clinical endpoints and should not yet drive adaptive treatment decisions.

DOI: 10.1186/s12880-026-02909-9​
​Open-access full text • CC BY 4.0

Accepted early article; publisher says further edits precede the final version.

PAST MONTH

3. ROAM: postoperative RT gains randomized evidence

Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial

Michael D Jenkinson; Anna Rosala-Hallas; Felix Sahm; et al.
The Lancet / EANO 2026 • Published 2026-09-25
CNS / WHO grade 2 meningioma • Postoperative fractionated RT
Keywords: Meningioma · Adjuvant RT · ROAM

ROAM/EORTC-1308 addresses whether radiotherapy should follow complete resection of atypical meningioma. In 157 randomized participants, investigators reported fewer recurrences with adjuvant radiation than observation. EORTC’s announcement reports recurrence in 14% versus 30% after a median five-year follow-up, without detected differences in quality of life or neurocognition. The findings strengthen postoperative counseling; individual risk and late effects remain relevant.

DOI: 10.1016/S0140-6736(26)01804-0​
​Open-access full text • CC BY 4.0

Counted once as the final paper; its EANO presentation is not a second item.

Numerical outcomes cross-checked in the official EORTC investigator press release.

LAST 6 MONTHS

4. Breast RT: baseline cardiac risk matters

Laterality of Breast Radiotherapy and Ischemic Heart Disease by Cardiovascular Risk Burden

Seung Yeun Chung; O Kyu Noh
JAMA Network Open • Published 2026-09-02
Breast • Postoperative RT / cardiac sparing
Keywords: Cardiac risk · Breast RT · Survivorship

A Korean claims-based cohort linked left-sided breast RT to a modest increase in ischemic heart disease overall. The association was significant in the subgroup with three cardiovascular risk factors, but not those with zero to two. The study supports attention to baseline cardiovascular burden and heart sparing. It lacks individual dosimetry and does not establish a threshold for withholding cardiac protection.

DOI: 10.1001/jamanetworkopen.2026.31356​
​Open-access full text • CC BY-NC-ND

Published 2026-09-02, outside the rolling 30-day window. A 2026-10-05 correction fixes a PDF running-head spelling only; no new outcome data.

ASTRO 2026

5. I-SABR: a mature phase II survival signal

Six-Year Overall Survival of Nivolumab Following Stereotactic Ablative Radiotherapy in Early-Stage Non-Small Cell Lung Cancer: Randomized I-SABR Trial

J. Y. Chang; S. H. Lin; W. Dong; et al.
ASTRO 2026 • Presented 2026-09-27
Lung • SABR plus nivolumab
Keywords: NSCLC · SABR · Immunotherapy

At 68.6 months’ median follow-up, adding four nivolumab doses to SABR produced six-year overall survival of 70% versus 56% and event-free survival of 53% versus 32%. The overall-survival hazard ratio was 0.548, with its 95% confidence interval reaching 1.000. This mature phase II signal merits confirmation and careful selection; it is not phase III evidence for routine immunotherapy after all early-stage SABR.

DOI: Not listed in the meeting portal; no matching DOI verified
​Complete public abstract • Freely readable complete conference abstract; no open reuse license stated

Conference-level evidence. Date is presentation date; the meeting portal is the accessible complete abstract, not a final journal manuscript.

ASTRO 2026

6. SOAR-HN: promising tolerability, substantial crossover

SOAR-HN: A Phase II Randomized Trial of Stereotactic Body Radiotherapy vs. Conventionally Fractionated Reirradiation for Previously Treated, Unresectable Head and Neck Cancer

L. F. Spurr; A. Lee; H. Wang; et al.
ASTRO 2026; IJROBP abstract supplement • Presented 2026-09-29
Head and Neck • SBRT / reirradiation
Keywords: Reirradiation · SBRT · Toxicity

In selected unresectable recurrent or second-primary head-and-neck cancer, two-year grade 3-or-higher toxicity was 6.7% with SBRT versus 23.9% with conventional reirradiation in the intention-to-treat analysis (P=0.073). The as-treated difference was larger, but 59% of conventional-arm patients crossed to SBRT. Survival comparisons were nonsignificant. The shorter approach warrants phase III study; these results do not establish equivalent cancer control.

DOI: 10.1016/j.ijrobp.2026.06.242​
​Complete public abstract • Freely readable complete conference abstract; no open reuse license stated

Conference-level evidence. Date is presentation date; the meeting portal is the accessible complete abstract, not a final journal manuscript.

ASTRO 2026

7. Spine SRS: no clear benefit from routine preventive cement

Prophylactic Cement Augmentation for Patients at High Risk for Developing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery: A Randomized Phase II Clinical Trial

A. J. Ghia; B. Amini; J. Li; et al.
ASTRO 2026; IJROBP abstract supplement • Presented 2026-09-30
Spine metastases • Single-fraction spine SRS / cement augmentation
Keywords: Spine SRS · Fracture · Stabilization

Among 60 participants in a preliminary intention-to-treat analysis, prophylactic cement augmentation after spine radiosurgery did not significantly reduce vertebral compression fractures (P=0.38). Four of 35 patients assigned to radiosurgery alone subsequently required salvage cement augmentation. These early data do not support routine prophylactic augmentation for every high-risk patient; further pain and fracture-severity analyses may clarify who benefits.

DOI: 10.1016/j.ijrobp.2026.06.267​
​Complete public abstract • Freely readable complete conference abstract; no open reuse license stated

Conference-level evidence. Date is presentation date; the meeting portal is the accessible complete abstract, not a final journal manuscript.

ASTRO 2026

8. Clonal hematopoiesis: a candidate post-treatment marker

Clonal Hematopoiesis Following Radiation Therapy as a Novel Predictor of Cancer Control and Survival: Analyses from Prospective Trials

K. T. Nead; T. Kim; A. D. Sherry; et al.
ASTRO 2026; IJROBP abstract supplement • Presented 2026-09-27
Oligometastatic solid tumors • Metastasis-directed RT / blood sequencing
Keywords: CHIP · Biomarkers · MDT

Blood analyses from two prospective trials associated expansion or acquisition of DNA-damage-repair clonal hematopoiesis after metastasis-directed treatment with poorer outcomes. Increased clone count was associated with worse overall survival (HR 2.23; 95% CI 1.17–4.26); baseline characteristics of clonal hematopoiesis were not. This is a prognostic association, not proof that changing RT based on blood sequencing improves outcomes.

DOI: 10.1016/j.ijrobp.2026.06.036​
​Complete public abstract • Freely readable complete conference abstract; no open reuse license stated

Conference-level evidence. Date is presentation date; the meeting portal is the accessible complete abstract, not a final journal manuscript.

ASTRO 2026

9. Merkel cell carcinoma: local control is not a survival claim

Nivolumab and Ipilimumab with or without Stereotactic Body Radiation in Advanced or Recurrent Merkel Cell Carcinoma: Long Term Results and Biomarker Analysis from a Phase II Multi-Institutional Study

S. Kim; E. Keit; J. Y. Nakashima; et al.
ASTRO 2026; IJROBP abstract supplement • Presented 2026-09-28
Skin / Merkel cell carcinoma • SBRT plus dual checkpoint inhibition
Keywords: Merkel cell · SBRT · Immunotherapy

Long-term follow-up showed durable responses to nivolumab–ipilimumab in immunotherapy-naive Merkel cell carcinoma and 100% five-year local control of irradiated lesions. Adding 24 Gy in three fractions did not produce a statistically significant survival or progression-free-survival advantage. Grade 3-or-higher treatment-related toxicity occurred in 44%. Strong local control should not be presented as demonstrated systemic benefit from SBRT.

DOI: 10.1016/j.ijrobp.2026.06.134​
​Complete public abstract • Freely readable complete conference abstract; no open reuse license stated

Conference-level evidence. Date is presentation date; the meeting portal is the accessible complete abstract, not a final journal manuscript.


Industry Updates

​Tampere introduces rectal HDR brachytherapy​
2026-10-07 • Tampere University / Tampere University Hospital • Treatment delivery / organ preservation
Institutional press release · Keywords: Brachytherapy · Rectal cancer · Organ preservation
​
Tampere reports introducing endorectal high-dose-rate brachytherapy using iridium-192, with multidisciplinary selection for an organ-preserving approach. Its institutional press release describes NORPPA-2 as planned for 2027. This is a service and research announcement, not a new comparative outcome report. The modality is HDR brachytherapy, not contact X-ray therapy.

​Telix–ITM merger agreement could reshape radiopharmaceutical supply​
2026-09-21 • Telix / ITM • Industry partnership / radiopharmaceuticals
Company press release;
corroborating SEC filing · Keywords: Radiopharmaceuticals · Isotope supply · Merger
​
Telix announced an agreement to combine with ITM, linking drug development, isotope production and manufacturing. The company describes potential supply and pipeline advantages; these are forward-looking claims. The announcement expects closing by the end of 2026, subject to shareholder and regulatory approvals and other conditions. Later October coverage does not change the September 21 announcement date or establish that the transaction has closed.

​Foundation volunteer applications close October 16​
2026-10-16 (event / deadline) • Speed of Light – The ASTRO Foundation • Professional society / research workforce
Official foundation announcement · Keywords: Research · Volunteering · Workforce
​
ASTRO members can apply by October 16 for foundation service beginning January 1, 2027. Opportunities include scientific review, research talent development, education and strategic initiatives. Applicants for the education and strategic initiatives group are asked to identify relevant expertise, including AI, functional radiation medicine, radiation–immune interactions or radiopharmaceutical therapy.

​ASTRO bylaws vote scheduled to open October 7​
2026-10-07 (scheduled voting started) · ASTRO · Professional society / governance
Official society announcement via ASTRO · Keywords: ASTRO; Physics; Governance
​
ASTRO’s published voting window runs October 7–November 6. Proposed changes include a dedicated physicist membership category with voting and leadership pathways, two at-large board seats and a phased transition to a smaller board. The window is now underway, but these remain proposals requiring member approval; no voting result is reported.


Spotlight on Patient Care

​HEAD-NECK-PET-CT: planning, imaging and outcome research​

Vallières M, Kay-Rivest E, Perrin LJ, et al. Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer. Sci Rep. 2017;7(1):10117. Published 2017 Aug 31. doi:10.1038/s41598-017-10371-5​

This retrospective multicenter resource links pretreatment PET/CT and radiation-planning data with outcomes after curative head-and-neck treatment. The original 300-patient study tested radiomic risk models across institutions; the current imaging collection contains 298 patients after two erroneous cases were excluded. It is a dataset study, not an interventional trial.

Case Summary: Four Quebec institutions; scans acquired 2006–2014. Dates are shifted consistently for deidentification. The original cohort excluded recurrent, initially metastatic and palliative cases. No individual patient narrative or identifiable image is reproduced.

Planning and Delivery: In the original 300-patient cohort, 48 received RT alone and 252 chemoradiation. Contours were drawn directly on PET/CT CT in 93 cases; 207 used planning-CT contours registered to PET/CT. This supports contour-registration and radiomics research, not a universal prescription.

Reported Outcomes: Independent test cohorts in the original study yielded AUC 0.69 for locoregional recurrence and 0.86 for distant metastasis using the reported combined models. These are model-performance measures, not treatment response or survival probabilities for any individual. Original cohort median follow-up was 43 months.

Investigator Profile: Martin Vallières, PhD, lead dataset author and scientific contact, is an associate professor in McGill’s Medical Physics Unit. His work combines AI and clinical sciences for precision medicine. Institutional profile​

Access and Licensing: Imaging is limited/controlled under the NIH Controlled Data Access Policy because facial reconstruction may be possible; apply through TCIA. Public clinical and GTV-name tables: CC BY 3.0. Code: GNU GPL. Cite collection DOI 10.7937/K9/TCIA.2017.8oje5q00; follow TCIA terms. No imaging downloaded or redistributed.


Clinical Trials to Watch

Registry status was checked 2026-10-06 through ClinicalTrials.gov. All 20 studies below were listed as recruiting, with at least one recruiting location. Coverage is based on site-level registry status, not direct confirmation of an open slot.

Clinical Trial

Details

Summary

Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer​
​NCT06008730​

Emory University
​Recruiting: Emory University Hospital/Winship Cancer Institute, Atlanta, United States​
Lung - Phase II

This phase II study evaluates postoperative proton therapy after complete resection when mediastinal nodal disease persists after preoperative systemic treatment. It targets a clinically difficult group needing improved locoregional control with limited cardiopulmonary exposure.

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer​
​NCT06686771​

Canadian Cancer Trials Group
​Recruiting: 75 registry-listed sites; Canada, United States​
Lung - Phase III

CURB2 tests whether ablating limited progressing lesions can improve disease control during first-line immunotherapy-based treatment for metastatic NSCLC. This phase III trial compares standard care with or without radiation to oligoprogressive sites.

A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)​
​NCT05417516​

Ontario Clinical Oncology Group (OCOG)
​Recruiting: 30 registry-listed sites; Australia, Canada​
Breast - Phase III

RAPID2 compares one-week partial-breast and whole-breast irradiation in selected node-negative patients after lumpectomy. The central question is whether a smaller treated volume can preserve control and improve the treatment experience within an already shortened schedule.

Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer​
​NCT05377047​

Vastra Gotaland Region
​Recruiting: 19 registry-listed sites; Ireland, Israel, Italy, Norway, Slovenia, Sweden​
Breast - Phase III

TAORMINA evaluates metastasis-directed SABR added to first-line systemic therapy in oligometastatic breast cancer. Its randomized design is important because results from mixed-histology oligometastatic studies cannot automatically be transferred to breast cancer.

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC​
​NCT04892173​

Johnson & Johnson Enterprise Innovation Inc.
​Recruiting: 133 sites across North America, Europe, South America and Asia (19 countries)​
Head and Neck - Phase III

NANORAY-312 tests tumor-injected JNJ-90301900 (NBTXR3), activated by radiotherapy with or without cetuximab, in older patients with locally advanced head-and-neck squamous cancer who cannot receive platinum chemotherapy.

Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)​
​NCT07513389​

Medical University of South Carolina
​Recruiting: Medical University of South Carolina, Charleston, United States​
Head and Neck - Phase II

OPERATION studies omission of adjuvant radiation after transoral surgery in tightly selected HPV-associated oropharyngeal cancer with favorable postoperative biomarker findings. This is experimental de-escalation under protocol surveillance, not a general recommendation to omit indicated postoperative RT.

Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma​
​NCT06516133​

Sun Yat-sen University
​Recruiting: Sun Yat-sen University Cancer Center, Guangzhou, China​
Head and Neck - Phase III

Adults aged 18–70 with newly diagnosed, nonmetastatic nasopharyngeal carcinoma are randomized to online adaptive IMRT with smaller planning margins or conventional IMRT with a 3 mm margin. This noninferiority study tests whether adaptation can reduce toxicity while preserving locoregional control.

Adaptive Versus Non-adaptive Radiotherapy and 2 Bladder Filling Instructions for Patients With Intermediate or High Risk Localized Prostate Cancer (ARP)​
​NCT06678126​

Scott Tyldesley
​Recruiting: BC Cancer Vancouver, Vancouver, Canada​
Prostate - Phase II

ARP examines daily online adaptation during moderately hypofractionated prostate and pelvic radiotherapy, with a parallel bladder-preparation comparison. The study is relevant to reproducibility, normal-tissue exposure and the staffing demands of adaptive treatment.

PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer​
​NCT07234981​

University of Nebraska
​Recruiting: University of Nebraska Medical Center, Omaha, United States​
Prostate - Phase II

This phase II study uses PSMA PET and MRI to personalize salvage radiation after prostatectomy. It evaluates a targeted approach in patients with visible pelvic or prostate-bed recurrence, while retaining systemic and elective-volume treatment specified by the protocol.

Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial​
​NCT06593431​

M.D. Anderson Cancer Center
​Recruiting: 4 registry-listed sites; United States​
Pancreas - Phase III

EXPAND is a phase III test of comprehensive local treatment added to systemic therapy for oligometastatic pancreatic cancer. Radiation is one permitted local modality. Progression-free and overall survival will determine whether promising earlier signals translate into broader benefit.

Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer​
​NCT07200141​

Peking Union Medical College Hospital
​Recruiting: Peking Union Medical College Hospital, Beijing, China​
Rectum - Phase II

This randomized phase II study tests whether a simultaneous integrated boost increases complete response in locally advanced rectal cancer. Both groups receive concurrent chemotherapy; subsequent surgery or observation depends on restaging and protocol-guided assessment.

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care​
​NCT07195591​

GT Medical Technologies, Inc.
​Recruiting: 13 registry-listed sites; United States​
Brain / Glioblastoma - Phase III

BRIDGES evaluates immediate surgically implanted radiation followed by shorter external-beam treatment against standard postoperative chemoradiation for newly diagnosed glioblastoma. The phase III design tests clinical benefit beyond the device’s existing clearance.

Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)​
​NCT07227610​

Medical University of South Carolina
​Recruiting: Medical University of South Carolina Hollings Cancer Center, Charleston, United States​
Brain metastases - Phase II

BIGSHOT compares staged stereotactic radiosurgery with fractionated stereotactic radiotherapy for large intact brain metastases. It addresses unresected lesions and competing stereotactic schedules, with local control and toxicity guiding the comparison.

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer​
​NCT07061977​

National Cancer Institute (NCI)
​Recruiting: 328 registry-listed sites; Puerto Rico, United States​
Cervix - Phase III

This phase III study tests systemic intensification before definitive chemoradiation in high-risk locally advanced cervical cancer. The comparison asks whether induction therapy improves outcomes beyond a chemoradiation-plus-pembrolizumab backbone.

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer​
​NCT07831902​

University College, London
​Recruiting: 12 registry-listed sites; United Kingdom​
Endometrium - Phase III

RAINBO NSMP-ORANGE tests molecularly selected adjuvant treatment for ER-positive NSMP endometrial cancer. It asks whether replacing chemotherapy with progestin after radiation can preserve efficacy while reducing toxicity and improving quality of life.

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi​
​NCT05929222​

Fondazione Italiana Linfomi - ETS
​Recruiting: 43 registry-listed sites; Italy​
Lymphoma - Phase III

GAZEBO evaluates whether adding obinutuzumab to radiation improves outcomes in early-stage follicular lymphoma. The study keeps a potentially curative local approach while testing whether systemic antibody treatment reduces subsequent relapse.

PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma​
​NCT07256158​

Fondazione Italiana Linfomi - ETS
​Recruiting: A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia, Torino, Italy​
Lymphoma - Phase III

PRIORITY tests involved-site radiation-dose reduction in early unfavorable Hodgkin lymphoma after PET-confirmed chemotherapy response. It asks whether reduced treatment intensity can maintain disease control while limiting late effects.

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss​
​NCT05382338​

Children's Oncology Group
​Recruiting: 107 registry-listed sites; Canada, United States​
Pediatric medulloblastoma - Phase III

ACNS2031 integrates hearing protection and risk-adapted therapy for pediatric medulloblastoma. The study includes sodium thiosulfate with chemotherapy and evaluates reduced radiation in selected low-risk disease, with central eligibility review essential before treatment assignment.

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)​
​NCT06239272​

St. Jude Children's Research Hospital
​Recruiting: 7 registry-listed sites; United States​
Pediatric soft-tissue sarcoma - Phase I/II

NRSTS2021 studies risk-adapted therapy for children and young adults with non-rhabdomyosarcoma soft-tissue sarcoma. Radiation questions include limited margins and dose escalation; systemic combinations differ by risk group, and not every participant receives radiation.

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma​
​NCT07049848​

M.D. Anderson Cancer Center
​Recruiting: The University of Texas M. D. Anderson Cancer Center, Houston, United States​
Soft-tissue sarcoma - Phase II

SATURN-STS evaluates doxorubicin and atezolizumab followed by preoperative radiation with atezolizumab, surgery and postoperative atezolizumab in adults with high-risk resectable extremity or superficial-trunk sarcoma. The phase II study measures relapse timing and safety.

PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)​
​NCT06074692​

Ruijin Hospital
​Recruiting: Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China​
Bone / Soft-tissue sarcoma - Phase II

PRIMA combines fluzoparib, camrelizumab and SBRT for previously treated, advanced bone or soft-tissue sarcoma. Patients aged 10–70 with measurable disease and lesions amenable to radiation enter histology-specific cohorts to assess activity, safety and exploratory biomarkers.


Did you know?

Radiotherapy bolus once included pantry staples.

A 1953 paper described rice and baking soda among earlier bolus materials—and explained why their radiation absorption and scattering properties could poorly approximate human tissue.

Lindsay and Stern developed a bolus material composed of approximately 2-mm beads made from 87% sucrose and 13% magnesium carbonate by weight, designed to pack consistently around irregular body surfaces while closely approximating the electron density of human tissue.

Nowadays, we don't use pantry staples, but we do use high tech 3D-printed baking molds to cast soft silicone bolus to follow patient contours. Maybe physicists come up with some of their best ideas in the kitchen?

Lindsay DD, Stern BE. A new tissue-like material for use as bolus. Radiology. 1953;60(3):355-362. doi:10.1148/60.3.355​

A Final Note

Thank you once again for joining us for this roundup of all things radiation oncology this week. If you found one portion of the newsletter more useful than others or have any feedback about what kind of content we could include, we'd love to hear more from you. You can provide us with any feedback about the content of the newsletter, submit content you'd like to see in the newsletter, or just say hi by sending an email to thisweekinradonc@gmail.com

Best,

This Week in RadOnc

This Week in RadOnc is your weekly guide to the research, technology, and industry developments shaping radiation oncology curated for clinicians, technologists, and industry professionals.

Read more from This Week in RadOnc

Volume 2, October 1st, 2026 Welcome back to This Week in Rad Onc! This week, we continue unpacking ASTRO’s findings, with a focus on shorter treatment courses, patient experience, and the evidence needed to bring new approaches into everyday practice. I’m particularly interested in how these developments affect the entire care team and patient outcomes. Alongside the research, you’ll find industry and reimbursement updates, a case spotlight, and recruiting trials in a more accessible format....

TWiRO at ASTRO 2026

First Edition - October 1st, 2026 Welcome to the first edition of This Week in Rad Onc, affectionately known as TWiRO. My name is Michael Owens. After attending ASTRO for the tenth time this year, I spoke with several colleagues who hadn't heard some of the biggest clinical and industry news announced at the meeting. It made me realize there was a need for a consolidated, trusted source covering both the clinical and industry developments that matter to those of us working in and around the...